Why Is Enliven Therapeutics Stock Trading Higher On Monday? - Enliven Therapeutics ( NASDAQ:ELVN )
HC Wainwright initiated coverage on Enliven Therapeutics, Inc. ELVN and noted the company as an emerging biotech company developing next-gen precision-oriented small molecules for solid and liquid tumor indications.
| Ticker |
Sentiment |
Impact |
|
AZN
|
Neutral
|
17 %
|
|
PFE
|
Neutral
|
17 %
|
|
BMY
|
Neutral
|
17 %
|
|
ELVN
|
Neutral
|
71 %
|
|
TAK
|
Neutral
|
17 %
|
